Prime Therapeutics earns URAC accreditation in pharmacy benefit management
By achieving this status, Prime has demonstrated a comprehensive commitment to quality care, improved processes and better patient outcomes
May 17, 2019
Prime has been providing PBM services for more than 20 years and now serves more than 28 million members nationally. Its mission is to make health care work better and help people get the medicine they need to feel better and live well. The company regularly pursues several accreditations to help improve service quality, and examine processes that enhance operations and compliance.
“As a company focused on providing total drug management, we aim to service our health plan and employer clients with the utmost quality,” said Renee Treberg, Chief Compliance Officer. “We are extremely proud to have been reaccredited by URAC in Pharmacy Benefit Management as it represents the gold standard in our industry and validates that Prime provides solid, high quality programs for our clients and their members. We hope people will see the URAC seal and know that we’ve been evaluated in a rigorous, meaningful way and that they can be confident doing business with us.”
URAC accreditation requires applicants to submit policies, procedures, and other organizational information that is followed by a review. The accreditation process demonstrates a commitment to quality services and serves as a framework to improve business processes through benchmarking organizations against nationally recognized standards.
“URAC accreditation shows that Prime is a pharmacy benefit management organization able to adhere to standards that cover important aspects of care such as claims processing, developing proper drug formulary, and consumer access,” said URAC President and CEO Shawn Griffin, M.D. “Quality policies and procedures are paramount as the price and complexity of medications rise. Prime Therapeutics chose to demonstrate their performance through URAC’s independent accreditation of their services.”
Prime’s accreditation is valid Jan. 1, 2019 through Jan. 1, 2022.
October 14, 2021
In first of its kind study, Prime Therapeutics explores paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates
EAGAN, Minn. – Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its…
October 6, 2021
Prime Therapeutics launches new MedsYourWay™ offering, now giving Blue Plan members home delivery prescription option using Amazon Pharmacy
EAGAN, Minn. – Prime Therapeutics LLC, a leading pharmacy benefit manager, announces its…
September 29, 2021
Prime Therapeutics and Pear Therapeutics announce first comprehensive value-based agreement for prescription digital therapeutics reSET® and reSET-O® for the treatment of substance and opioid use disorders
BOSTON and EAGAN, Minn. – More than 20 million Americans struggle with drug…